uniQure N.V. (QURE)

37.53 -0.55 (-1.44%) At close: 4:00PM EST

uniQure N.V.

Paasheuvelweg 25a
Amsterdam 1105 BP
Netherlands
31 20 240 6000
http://www.uniqure.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 248

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Matthew Craig Kapusta	CEO, CFO & Exec. Director	908.63k	459.12k	1972
Dr. Alexander E. Kuta Ph.D.	Exec. VP of Operations	610.61k	2.42M	1960
Prof. Hugo Katus	Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany	N/A	N/A	N/A
Mr. Christian Klemt	Chief Accounting Officer	N/A	N/A	1973
Mr. David Cerveny	Chief Legal Officer, Gen. Counsel & Sec.	N/A	N/A	1967
Ms. Maria E. Cantor	Chief Communications Officer	N/A	N/A	1968
Dr. Tamara Tugal Ph.D., MBA	Bus. Devel. Director	N/A	N/A	N/A
Mr. James Brady	Chief HR Officer	N/A	N/A	N/A
Mr. Jonathan Garen M.S.	Chief Bus. Officer	N/A	N/A	1966
Mr. Ricardo Dolmetsch Ph.D.	Pres of R&D	N/A	N/A	1969

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

uniQure N.V., a gene therapy company, engages in the development and commercialization of treatments for patients suffering from genetic and other diseases in the Netherlands. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment of hemophilia A; and AMT-190, an IV-administered adeno-associated virus 5-based gene therapy for the treatment of Fabry disease. In addition, it engages in developing AMT-150, a gene therapy candidate for the treatment of Spinocerebellar Ataxia Type 3 disease. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Corporate Governance

uniQure N.V.’s ISS Governance QualityScore as of December 1, 2020 is 2. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.